Thesis

General introduction and thesis outline 31 1 18. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370(9590): 890-907. 19. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357(9271): 1831-6. 20. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002; 109(1): 96-8. 21. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24 Suppl 3: S3/5261. 22. Syrjanen K, Hakama M, Saarikoski S, Vayrynen M, Yliskoski M, Syrjanen S, et al. Prevalence, incidence, and estimated lifetime risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis 1990; 17(1): 15-9. 23. Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008; 98(3): 646-51. 24. Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007; 96(9): 1419-24. 25. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi) genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014; 14(6): 395-405. 26. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7(1): 11-22. 27. Gissmann L, Boshart M, Durst M, Ikenberg H, Wagner D, zur Hausen H. Presence of human papillomavirus in genital tumors. J Invest Dermatol 1984; 83(1 Suppl): 26s-8s. 28. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324(1): 17-27. 29. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110(5): 52541. 30. McBride AA. Human papillomaviruses: diversity, infection and host interactions. Nat Rev Microbiol 2022; 20(2): 95-108. 31. de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology 2013; 445(1-2): 2-10. 32. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009; 10(4): 321-2. 33. Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol 2014; 234(4): 441-51. 34. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11(11): 1048-56. 35. Clifford G, Franceschi S. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer 2008; 122(7): 1684-5. 36. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31 Suppl 8: I1-31.

RkJQdWJsaXNoZXIy MjY0ODMw